Search

MGN-4893

MGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]

Lycopene

Lycopene is a naturally occurring red carotenoid pigment that is responsible for red to pink colors seen in tomatoes, pink grapefruit, and other foods [A27242].

F-15599

Talc

In fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent. … Although talc has been widely used for decades, lawsuits that have come to the surface claim serious health complications linked to its use.

Nirmatrelvir

mild-to-moderate COVID-19. … [L33359] Both drugs were inhibitors of SARS-CoV-2 3CL^PRO, but nirmatrelvir has the advantage of being orally bioavailable.

Riltozinameran

[L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … [L43917] As of November 2022, it is the primary circulating variant of concern according to the World Health Organization.

Nomifensine

Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets. … FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)).

Pixantrone

It is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox … Patients refractory to treatment, or those who relapse, are discouraged from further anthracycline use due to cumulative cardiotoxicity.

Ammonia

Ammonia gas has been used in the clinical setting as a respiratory stimulant to prevent fainting. … It is proposed that human adults produce about 1000 mmol of ammonia daily, most of which undergoes excretion in the urine.

Aficamten

[L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and … [L54783] Aficamten works by attenuating myocardial hypercontractility and left ventricular outflow tract obstruction, which are characteristics of oHCM.[A275293]